nodes	percent_of_prediction	percent_of_DWPC	metapath
Riluzole—ABCG2—Teniposide—lymphatic system cancer	0.214	0.324	CbGbCtD
Riluzole—ABCG2—Mitoxantrone—lymphatic system cancer	0.15	0.227	CbGbCtD
Riluzole—CYP1A2—Carmustine—lymphatic system cancer	0.131	0.199	CbGbCtD
Riluzole—ABCG2—Vincristine—lymphatic system cancer	0.103	0.156	CbGbCtD
Riluzole—ABCG2—Methotrexate—lymphatic system cancer	0.0624	0.0944	CbGbCtD
Riluzole—Confusional state—Bleomycin—lymphatic system cancer	0.000291	0.000858	CcSEcCtD
Riluzole—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00029	0.000855	CcSEcCtD
Riluzole—Tremor—Carmustine—lymphatic system cancer	0.000289	0.000853	CcSEcCtD
Riluzole—Oedema—Bleomycin—lymphatic system cancer	0.000288	0.000851	CcSEcCtD
Riluzole—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000288	0.000851	CcSEcCtD
Riluzole—Infection—Bleomycin—lymphatic system cancer	0.000286	0.000846	CcSEcCtD
Riluzole—Anaemia—Carmustine—lymphatic system cancer	0.000285	0.000842	CcSEcCtD
Riluzole—Back pain—Vincristine—lymphatic system cancer	0.000285	0.000841	CcSEcCtD
Riluzole—Vomiting—Teniposide—lymphatic system cancer	0.000285	0.00084	CcSEcCtD
Riluzole—Sepsis—Methotrexate—lymphatic system cancer	0.000284	0.000837	CcSEcCtD
Riluzole—Agitation—Carmustine—lymphatic system cancer	0.000283	0.000837	CcSEcCtD
Riluzole—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000282	0.000833	CcSEcCtD
Riluzole—Asthenia—Fludarabine—lymphatic system cancer	0.000282	0.000833	CcSEcCtD
Riluzole—Rash—Teniposide—lymphatic system cancer	0.000282	0.000833	CcSEcCtD
Riluzole—Dermatitis—Teniposide—lymphatic system cancer	0.000282	0.000832	CcSEcCtD
Riluzole—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000281	0.000829	CcSEcCtD
Riluzole—Headache—Teniposide—lymphatic system cancer	0.00028	0.000828	CcSEcCtD
Riluzole—Pruritus—Fludarabine—lymphatic system cancer	0.000278	0.000821	CcSEcCtD
Riluzole—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000278	0.000821	CcSEcCtD
Riluzole—Back pain—Mitoxantrone—lymphatic system cancer	0.000277	0.000819	CcSEcCtD
Riluzole—Leukopenia—Carmustine—lymphatic system cancer	0.000276	0.000815	CcSEcCtD
Riluzole—Anorexia—Bleomycin—lymphatic system cancer	0.000275	0.000811	CcSEcCtD
Riluzole—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000273	0.000805	CcSEcCtD
Riluzole—Anaemia—Vincristine—lymphatic system cancer	0.000272	0.000803	CcSEcCtD
Riluzole—Agitation—Vincristine—lymphatic system cancer	0.000271	0.000799	CcSEcCtD
Riluzole—Photosensitivity—Methotrexate—lymphatic system cancer	0.00027	0.000797	CcSEcCtD
Riluzole—Hypotension—Bleomycin—lymphatic system cancer	0.000269	0.000795	CcSEcCtD
Riluzole—Diarrhoea—Fludarabine—lymphatic system cancer	0.000269	0.000794	CcSEcCtD
Riluzole—Convulsion—Carmustine—lymphatic system cancer	0.000267	0.000789	CcSEcCtD
Riluzole—Hypertension—Carmustine—lymphatic system cancer	0.000266	0.000786	CcSEcCtD
Riluzole—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000266	0.000785	CcSEcCtD
Riluzole—Nausea—Teniposide—lymphatic system cancer	0.000266	0.000785	CcSEcCtD
Riluzole—Anaemia—Mitoxantrone—lymphatic system cancer	0.000265	0.000782	CcSEcCtD
Riluzole—Vertigo—Vincristine—lymphatic system cancer	0.000265	0.000781	CcSEcCtD
Riluzole—Leukopenia—Vincristine—lymphatic system cancer	0.000264	0.000778	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000263	0.000776	CcSEcCtD
Riluzole—Chest pain—Carmustine—lymphatic system cancer	0.000263	0.000775	CcSEcCtD
Riluzole—Myalgia—Carmustine—lymphatic system cancer	0.000263	0.000775	CcSEcCtD
Riluzole—Anxiety—Carmustine—lymphatic system cancer	0.000262	0.000772	CcSEcCtD
Riluzole—Paraesthesia—Bleomycin—lymphatic system cancer	0.000259	0.000764	CcSEcCtD
Riluzole—Malaise—Mitoxantrone—lymphatic system cancer	0.000259	0.000763	CcSEcCtD
Riluzole—Dyspnoea—Bleomycin—lymphatic system cancer	0.000257	0.000759	CcSEcCtD
Riluzole—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000257	0.000758	CcSEcCtD
Riluzole—Convulsion—Vincristine—lymphatic system cancer	0.000255	0.000753	CcSEcCtD
Riluzole—Hypertension—Vincristine—lymphatic system cancer	0.000254	0.00075	CcSEcCtD
Riluzole—Confusional state—Carmustine—lymphatic system cancer	0.000254	0.000749	CcSEcCtD
Riluzole—Oedema—Carmustine—lymphatic system cancer	0.000252	0.000743	CcSEcCtD
Riluzole—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000251	0.000742	CcSEcCtD
Riluzole—Decreased appetite—Bleomycin—lymphatic system cancer	0.000251	0.00074	CcSEcCtD
Riluzole—Myalgia—Vincristine—lymphatic system cancer	0.000251	0.00074	CcSEcCtD
Riluzole—Cough—Mitoxantrone—lymphatic system cancer	0.00025	0.000739	CcSEcCtD
Riluzole—Infection—Carmustine—lymphatic system cancer	0.00025	0.000738	CcSEcCtD
Riluzole—Vomiting—Fludarabine—lymphatic system cancer	0.00025	0.000738	CcSEcCtD
Riluzole—Convulsion—Mitoxantrone—lymphatic system cancer	0.000248	0.000733	CcSEcCtD
Riluzole—Rash—Fludarabine—lymphatic system cancer	0.000248	0.000732	CcSEcCtD
Riluzole—Dermatitis—Fludarabine—lymphatic system cancer	0.000248	0.000731	CcSEcCtD
Riluzole—Hypertension—Mitoxantrone—lymphatic system cancer	0.000248	0.000731	CcSEcCtD
Riluzole—Pain—Bleomycin—lymphatic system cancer	0.000247	0.000728	CcSEcCtD
Riluzole—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000246	0.000728	CcSEcCtD
Riluzole—Headache—Fludarabine—lymphatic system cancer	0.000246	0.000727	CcSEcCtD
Riluzole—Tachycardia—Carmustine—lymphatic system cancer	0.000246	0.000725	CcSEcCtD
Riluzole—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000245	0.000724	CcSEcCtD
Riluzole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000244	0.000721	CcSEcCtD
Riluzole—Chest pain—Mitoxantrone—lymphatic system cancer	0.000244	0.000721	CcSEcCtD
Riluzole—Myalgia—Mitoxantrone—lymphatic system cancer	0.000244	0.000721	CcSEcCtD
Riluzole—Anxiety—Mitoxantrone—lymphatic system cancer	0.000243	0.000718	CcSEcCtD
Riluzole—Discomfort—Mitoxantrone—lymphatic system cancer	0.000241	0.000712	CcSEcCtD
Riluzole—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00024	0.000709	CcSEcCtD
Riluzole—Oedema—Vincristine—lymphatic system cancer	0.00024	0.000709	CcSEcCtD
Riluzole—Anorexia—Carmustine—lymphatic system cancer	0.00024	0.000708	CcSEcCtD
Riluzole—Infection—Vincristine—lymphatic system cancer	0.000239	0.000705	CcSEcCtD
Riluzole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000238	0.000701	CcSEcCtD
Riluzole—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000237	0.0007	CcSEcCtD
Riluzole—Confusional state—Mitoxantrone—lymphatic system cancer	0.000236	0.000697	CcSEcCtD
Riluzole—Nervous system disorder—Vincristine—lymphatic system cancer	0.000236	0.000696	CcSEcCtD
Riluzole—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000235	0.000695	CcSEcCtD
Riluzole—Hypotension—Carmustine—lymphatic system cancer	0.000235	0.000694	CcSEcCtD
Riluzole—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000234	0.000691	CcSEcCtD
Riluzole—Oedema—Mitoxantrone—lymphatic system cancer	0.000234	0.000691	CcSEcCtD
Riluzole—Nausea—Fludarabine—lymphatic system cancer	0.000234	0.00069	CcSEcCtD
Riluzole—Infection—Mitoxantrone—lymphatic system cancer	0.000232	0.000686	CcSEcCtD
Riluzole—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000232	0.000686	CcSEcCtD
Riluzole—Shock—Mitoxantrone—lymphatic system cancer	0.00023	0.00068	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000229	0.000677	CcSEcCtD
Riluzole—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000229	0.000676	CcSEcCtD
Riluzole—Urticaria—Bleomycin—lymphatic system cancer	0.000229	0.000676	CcSEcCtD
Riluzole—Anorexia—Vincristine—lymphatic system cancer	0.000229	0.000676	CcSEcCtD
Riluzole—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000228	0.000674	CcSEcCtD
Riluzole—Body temperature increased—Bleomycin—lymphatic system cancer	0.000228	0.000673	CcSEcCtD
Riluzole—Insomnia—Carmustine—lymphatic system cancer	0.000228	0.000672	CcSEcCtD
Riluzole—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000227	0.000671	CcSEcCtD
Riluzole—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000226	0.000668	CcSEcCtD
Riluzole—Paraesthesia—Carmustine—lymphatic system cancer	0.000226	0.000667	CcSEcCtD
Riluzole—Mood swings—Methotrexate—lymphatic system cancer	0.000225	0.000663	CcSEcCtD
Riluzole—Hypotension—Vincristine—lymphatic system cancer	0.000225	0.000663	CcSEcCtD
Riluzole—Dyspnoea—Carmustine—lymphatic system cancer	0.000224	0.000662	CcSEcCtD
Riluzole—Somnolence—Carmustine—lymphatic system cancer	0.000224	0.000661	CcSEcCtD
Riluzole—Anorexia—Mitoxantrone—lymphatic system cancer	0.000223	0.000658	CcSEcCtD
Riluzole—Ataxia—Methotrexate—lymphatic system cancer	0.000223	0.000658	CcSEcCtD
Riluzole—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000219	0.000647	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000219	0.000646	CcSEcCtD
Riluzole—Decreased appetite—Carmustine—lymphatic system cancer	0.000219	0.000646	CcSEcCtD
Riluzole—Hypotension—Mitoxantrone—lymphatic system cancer	0.000219	0.000645	CcSEcCtD
Riluzole—Insomnia—Vincristine—lymphatic system cancer	0.000217	0.000642	CcSEcCtD
Riluzole—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000217	0.000642	CcSEcCtD
Riluzole—Paraesthesia—Vincristine—lymphatic system cancer	0.000216	0.000637	CcSEcCtD
Riluzole—Pain—Carmustine—lymphatic system cancer	0.000215	0.000635	CcSEcCtD
Riluzole—Constipation—Carmustine—lymphatic system cancer	0.000215	0.000635	CcSEcCtD
Riluzole—Breast disorder—Methotrexate—lymphatic system cancer	0.000214	0.000633	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000213	0.000629	CcSEcCtD
Riluzole—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000212	0.000627	CcSEcCtD
Riluzole—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00021	0.00062	CcSEcCtD
Riluzole—Decreased appetite—Vincristine—lymphatic system cancer	0.000209	0.000617	CcSEcCtD
Riluzole—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000209	0.000616	CcSEcCtD
Riluzole—Somnolence—Mitoxantrone—lymphatic system cancer	0.000208	0.000614	CcSEcCtD
Riluzole—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000207	0.000612	CcSEcCtD
Riluzole—Feeling abnormal—Carmustine—lymphatic system cancer	0.000207	0.000612	CcSEcCtD
Riluzole—Fatigue—Vincristine—lymphatic system cancer	0.000207	0.000612	CcSEcCtD
Riluzole—Asthenia—Bleomycin—lymphatic system cancer	0.000207	0.000611	CcSEcCtD
Riluzole—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000206	0.000608	CcSEcCtD
Riluzole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000206	0.000608	CcSEcCtD
Riluzole—Pain—Vincristine—lymphatic system cancer	0.000205	0.000607	CcSEcCtD
Riluzole—Constipation—Vincristine—lymphatic system cancer	0.000205	0.000607	CcSEcCtD
Riluzole—Asthma—Methotrexate—lymphatic system cancer	0.000205	0.000605	CcSEcCtD
Riluzole—Pruritus—Bleomycin—lymphatic system cancer	0.000204	0.000602	CcSEcCtD
Riluzole—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000203	0.000601	CcSEcCtD
Riluzole—Fatigue—Mitoxantrone—lymphatic system cancer	0.000202	0.000596	CcSEcCtD
Riluzole—Pancreatitis—Methotrexate—lymphatic system cancer	0.000201	0.000593	CcSEcCtD
Riluzole—Pain—Mitoxantrone—lymphatic system cancer	0.0002	0.000591	CcSEcCtD
Riluzole—Constipation—Mitoxantrone—lymphatic system cancer	0.0002	0.000591	CcSEcCtD
Riluzole—Body temperature increased—Carmustine—lymphatic system cancer	0.000199	0.000587	CcSEcCtD
Riluzole—Abdominal pain—Carmustine—lymphatic system cancer	0.000199	0.000587	CcSEcCtD
Riluzole—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000197	0.00058	CcSEcCtD
Riluzole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000196	0.00058	CcSEcCtD
Riluzole—Pancytopenia—Methotrexate—lymphatic system cancer	0.000195	0.000575	CcSEcCtD
Riluzole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000193	0.000569	CcSEcCtD
Riluzole—Dysuria—Methotrexate—lymphatic system cancer	0.000192	0.000566	CcSEcCtD
Riluzole—Neutropenia—Methotrexate—lymphatic system cancer	0.000192	0.000566	CcSEcCtD
Riluzole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000191	0.000565	CcSEcCtD
Riluzole—Abdominal pain—Vincristine—lymphatic system cancer	0.00019	0.000561	CcSEcCtD
Riluzole—Body temperature increased—Vincristine—lymphatic system cancer	0.00019	0.000561	CcSEcCtD
Riluzole—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000189	0.000557	CcSEcCtD
Riluzole—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000187	0.000552	CcSEcCtD
Riluzole—Urticaria—Mitoxantrone—lymphatic system cancer	0.000186	0.000549	CcSEcCtD
Riluzole—Hypersensitivity—Carmustine—lymphatic system cancer	0.000185	0.000547	CcSEcCtD
Riluzole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000185	0.000546	CcSEcCtD
Riluzole—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000185	0.000546	CcSEcCtD
Riluzole—Pneumonia—Methotrexate—lymphatic system cancer	0.000184	0.000543	CcSEcCtD
Riluzole—Vomiting—Bleomycin—lymphatic system cancer	0.000183	0.000541	CcSEcCtD
Riluzole—Infestation—Methotrexate—lymphatic system cancer	0.000183	0.00054	CcSEcCtD
Riluzole—Infestation NOS—Methotrexate—lymphatic system cancer	0.000183	0.00054	CcSEcCtD
Riluzole—Depression—Methotrexate—lymphatic system cancer	0.000182	0.000538	CcSEcCtD
Riluzole—Rash—Bleomycin—lymphatic system cancer	0.000182	0.000537	CcSEcCtD
Riluzole—Dermatitis—Bleomycin—lymphatic system cancer	0.000182	0.000536	CcSEcCtD
Riluzole—Asthenia—Carmustine—lymphatic system cancer	0.000181	0.000533	CcSEcCtD
Riluzole—Stomatitis—Methotrexate—lymphatic system cancer	0.000178	0.000526	CcSEcCtD
Riluzole—Hypersensitivity—Vincristine—lymphatic system cancer	0.000177	0.000523	CcSEcCtD
Riluzole—Sweating—Methotrexate—lymphatic system cancer	0.000175	0.000517	CcSEcCtD
Riluzole—Haematuria—Methotrexate—lymphatic system cancer	0.000174	0.000515	CcSEcCtD
Riluzole—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000173	0.00051	CcSEcCtD
Riluzole—Epistaxis—Methotrexate—lymphatic system cancer	0.000172	0.000509	CcSEcCtD
Riluzole—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000172	0.000509	CcSEcCtD
Riluzole—Asthenia—Vincristine—lymphatic system cancer	0.000172	0.000509	CcSEcCtD
Riluzole—Diarrhoea—Carmustine—lymphatic system cancer	0.000172	0.000508	CcSEcCtD
Riluzole—Nausea—Bleomycin—lymphatic system cancer	0.000171	0.000506	CcSEcCtD
Riluzole—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000171	0.000504	CcSEcCtD
Riluzole—Asthenia—Mitoxantrone—lymphatic system cancer	0.000168	0.000496	CcSEcCtD
Riluzole—Dizziness—Carmustine—lymphatic system cancer	0.000166	0.000491	CcSEcCtD
Riluzole—Haemoglobin—Methotrexate—lymphatic system cancer	0.000165	0.000487	CcSEcCtD
Riluzole—Diarrhoea—Vincristine—lymphatic system cancer	0.000164	0.000485	CcSEcCtD
Riluzole—Haemorrhage—Methotrexate—lymphatic system cancer	0.000164	0.000484	CcSEcCtD
Riluzole—Hepatitis—Methotrexate—lymphatic system cancer	0.000164	0.000484	CcSEcCtD
Riluzole—Pharyngitis—Methotrexate—lymphatic system cancer	0.000163	0.000481	CcSEcCtD
Riluzole—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000162	0.000478	CcSEcCtD
Riluzole—Urethral disorder—Methotrexate—lymphatic system cancer	0.000161	0.000475	CcSEcCtD
Riluzole—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00016	0.000473	CcSEcCtD
Riluzole—Vomiting—Carmustine—lymphatic system cancer	0.00016	0.000472	CcSEcCtD
Riluzole—Dizziness—Vincristine—lymphatic system cancer	0.000159	0.000469	CcSEcCtD
Riluzole—Rash—Carmustine—lymphatic system cancer	0.000159	0.000469	CcSEcCtD
Riluzole—Dermatitis—Carmustine—lymphatic system cancer	0.000159	0.000468	CcSEcCtD
Riluzole—Headache—Carmustine—lymphatic system cancer	0.000158	0.000465	CcSEcCtD
Riluzole—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000155	0.000458	CcSEcCtD
Riluzole—Eye disorder—Methotrexate—lymphatic system cancer	0.000153	0.000453	CcSEcCtD
Riluzole—Vomiting—Vincristine—lymphatic system cancer	0.000153	0.000451	CcSEcCtD
Riluzole—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000152	0.00045	CcSEcCtD
Riluzole—Rash—Vincristine—lymphatic system cancer	0.000152	0.000447	CcSEcCtD
Riluzole—Dermatitis—Vincristine—lymphatic system cancer	0.000151	0.000447	CcSEcCtD
Riluzole—Headache—Vincristine—lymphatic system cancer	0.000151	0.000444	CcSEcCtD
Riluzole—Nausea—Carmustine—lymphatic system cancer	0.00015	0.000441	CcSEcCtD
Riluzole—Angiopathy—Methotrexate—lymphatic system cancer	0.000149	0.00044	CcSEcCtD
Riluzole—Vomiting—Mitoxantrone—lymphatic system cancer	0.000149	0.000439	CcSEcCtD
Riluzole—Immune system disorder—Methotrexate—lymphatic system cancer	0.000148	0.000438	CcSEcCtD
Riluzole—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000148	0.000437	CcSEcCtD
Riluzole—Rash—Mitoxantrone—lymphatic system cancer	0.000148	0.000436	CcSEcCtD
Riluzole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000147	0.000435	CcSEcCtD
Riluzole—Chills—Methotrexate—lymphatic system cancer	0.000147	0.000435	CcSEcCtD
Riluzole—Headache—Mitoxantrone—lymphatic system cancer	0.000147	0.000433	CcSEcCtD
Riluzole—Alopecia—Methotrexate—lymphatic system cancer	0.000145	0.000428	CcSEcCtD
Riluzole—Mental disorder—Methotrexate—lymphatic system cancer	0.000144	0.000424	CcSEcCtD
Riluzole—Malnutrition—Methotrexate—lymphatic system cancer	0.000143	0.000422	CcSEcCtD
Riluzole—Nausea—Vincristine—lymphatic system cancer	0.000143	0.000421	CcSEcCtD
Riluzole—Dysgeusia—Methotrexate—lymphatic system cancer	0.00014	0.000413	CcSEcCtD
Riluzole—Nausea—Mitoxantrone—lymphatic system cancer	0.000139	0.00041	CcSEcCtD
Riluzole—Back pain—Methotrexate—lymphatic system cancer	0.000138	0.000408	CcSEcCtD
Riluzole—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000133	0.000391	CcSEcCtD
Riluzole—Anaemia—Methotrexate—lymphatic system cancer	0.000132	0.00039	CcSEcCtD
Riluzole—Malaise—Methotrexate—lymphatic system cancer	0.000129	0.00038	CcSEcCtD
Riluzole—Vertigo—Methotrexate—lymphatic system cancer	0.000128	0.000379	CcSEcCtD
Riluzole—Leukopenia—Methotrexate—lymphatic system cancer	0.000128	0.000377	CcSEcCtD
Riluzole—Cough—Methotrexate—lymphatic system cancer	0.000125	0.000368	CcSEcCtD
Riluzole—Convulsion—Methotrexate—lymphatic system cancer	0.000124	0.000365	CcSEcCtD
Riluzole—Myalgia—Methotrexate—lymphatic system cancer	0.000122	0.000359	CcSEcCtD
Riluzole—Arthralgia—Methotrexate—lymphatic system cancer	0.000122	0.000359	CcSEcCtD
Riluzole—Chest pain—Methotrexate—lymphatic system cancer	0.000122	0.000359	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000121	0.000357	CcSEcCtD
Riluzole—Discomfort—Methotrexate—lymphatic system cancer	0.00012	0.000355	CcSEcCtD
Riluzole—Confusional state—Methotrexate—lymphatic system cancer	0.000118	0.000347	CcSEcCtD
Riluzole—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000117	0.000344	CcSEcCtD
Riluzole—Infection—Methotrexate—lymphatic system cancer	0.000116	0.000342	CcSEcCtD
Riluzole—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000114	0.000338	CcSEcCtD
Riluzole—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000114	0.000337	CcSEcCtD
Riluzole—Skin disorder—Methotrexate—lymphatic system cancer	0.000113	0.000334	CcSEcCtD
Riluzole—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000113	0.000333	CcSEcCtD
Riluzole—Anorexia—Methotrexate—lymphatic system cancer	0.000111	0.000328	CcSEcCtD
Riluzole—Hypotension—Methotrexate—lymphatic system cancer	0.000109	0.000322	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000106	0.000314	CcSEcCtD
Riluzole—Insomnia—Methotrexate—lymphatic system cancer	0.000105	0.000311	CcSEcCtD
Riluzole—Paraesthesia—Methotrexate—lymphatic system cancer	0.000105	0.000309	CcSEcCtD
Riluzole—Dyspnoea—Methotrexate—lymphatic system cancer	0.000104	0.000307	CcSEcCtD
Riluzole—Somnolence—Methotrexate—lymphatic system cancer	0.000104	0.000306	CcSEcCtD
Riluzole—Dyspepsia—Methotrexate—lymphatic system cancer	0.000103	0.000303	CcSEcCtD
Riluzole—Decreased appetite—Methotrexate—lymphatic system cancer	0.000101	0.000299	CcSEcCtD
Riluzole—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000101	0.000297	CcSEcCtD
Riluzole—Fatigue—Methotrexate—lymphatic system cancer	0.000101	0.000297	CcSEcCtD
Riluzole—Pain—Methotrexate—lymphatic system cancer	9.97e-05	0.000294	CcSEcCtD
Riluzole—Feeling abnormal—Methotrexate—lymphatic system cancer	9.61e-05	0.000284	CcSEcCtD
Riluzole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	9.53e-05	0.000281	CcSEcCtD
Riluzole—Urticaria—Methotrexate—lymphatic system cancer	9.26e-05	0.000273	CcSEcCtD
Riluzole—Abdominal pain—Methotrexate—lymphatic system cancer	9.22e-05	0.000272	CcSEcCtD
Riluzole—Body temperature increased—Methotrexate—lymphatic system cancer	9.22e-05	0.000272	CcSEcCtD
Riluzole—Hypersensitivity—Methotrexate—lymphatic system cancer	8.59e-05	0.000254	CcSEcCtD
Riluzole—Asthenia—Methotrexate—lymphatic system cancer	8.36e-05	0.000247	CcSEcCtD
Riluzole—Pruritus—Methotrexate—lymphatic system cancer	8.25e-05	0.000244	CcSEcCtD
Riluzole—Diarrhoea—Methotrexate—lymphatic system cancer	7.98e-05	0.000235	CcSEcCtD
Riluzole—Dizziness—Methotrexate—lymphatic system cancer	7.71e-05	0.000228	CcSEcCtD
Riluzole—Vomiting—Methotrexate—lymphatic system cancer	7.41e-05	0.000219	CcSEcCtD
Riluzole—Rash—Methotrexate—lymphatic system cancer	7.35e-05	0.000217	CcSEcCtD
Riluzole—Dermatitis—Methotrexate—lymphatic system cancer	7.34e-05	0.000217	CcSEcCtD
Riluzole—Headache—Methotrexate—lymphatic system cancer	7.3e-05	0.000216	CcSEcCtD
Riluzole—Nausea—Methotrexate—lymphatic system cancer	6.93e-05	0.000204	CcSEcCtD
